Search Results

Enable Biosciences Inc. is elated to announce its receipt of a Phase IIB Small Business Innovation Research (SBIR) award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Findings from the landmark FLOW trial, the first dedicated kidney outcomes trial with a GLP-1 receptor agonist were reported, demonstrating semaglutide significantly reduces the risk of major kidney disease events and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease.

Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a Small Business Technology Transfer (STTR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) division of the National Institute of Health (NIH).

As March approaches, the National Kidney Foundation is gearing up to observe National Kidney Month, a crucial time dedicated to raising awareness about kidney health and chronic kidney disease.

Findings from the ATTEMPT study, showed that a low-dose of SGLT2 inhibitor could safely be given to youth and adolescents with type 1 diabetes to improve kidney function and glycemic management.

Wexford Science & Technology, LLC announced that the National Institutes of Health has signed a lease at 850 PBC and will use the space to accommodate the Phoenix Epidemiology & Clinical Research Branch of the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases.

AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®.

Panbela Therapeutics, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, announces an oral presentation at the Digestive Disease Week conference, which was held May 18-21, 2024.